Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$57.59
-$1.46(-0.68%)
At close: 4:00 PM EST
$57.59
-$1.46(-0.68%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume95.34K
Average Volume (3M)1.07M
Market Cap
$1.48B
Enterprise Value$1.12B
Total Cash (Recent Filing)$283.83M
Total Debt (Recent Filing)$29.55M
Price to Earnings (P/E)11.5
Beta0.60
Next Earnings
Aug 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.53
Shares Outstanding28,813,152
10 Day Avg. Volume1,359,144
30 Day Avg. Volume1,069,062
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda13.93
Forecast
1Y Price Target
$51.91Price Target Upside-9.86% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.9
Revenue Forecast (FY)$843.82M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained gross margins above ~85% indicate strong product-level economics and pricing power for an implanted therapy. High margins provide structural resilience to reimbursement pressure, enable reinvestment in commercialization and R&D, and support long-term profitability even if volumes fluctuate.
Strong Balance Sheet And LiquidityA large cash balance with no meaningful debt and a debt-to-equity near 0.04 materially reduces refinancing and solvency risk. This liquidity gives the company runway to absorb multi-year reimbursement disruption, invest in payer education, and fund clinical/commercial initiatives without near-term funding needs.
Robust Clinical Evidence And Installed BaseExtensive clinical data and a large installed base drive durable physician confidence, referral networks, and replacement procedure demand. Strong outcomes and published studies materially support long-term adoption, payer negotiations, and defendability versus competitors entering the OSA space.
Bears Say
Coding And Payer AmbiguityPersistent coding differences across payers create structural case approval friction, increasing administrative burden and delaying procedures. Because a permanent CPT solution isn't expected until 2028, this reduces revenue predictability, raises commercial costs, and hampers consistent procedure volumes for multiple quarters.
WISER Prior-authorization HeadwindAI-driven prior authorization in pilot states has materially slowed Medicare approvals, creating multi‑tens of millions of dollars of lost near‑term procedures. If prior authorization expands or persists, it structurally depresses throughput, extends cash conversion cycles, and forces higher customer support and payer-engagement spend.
Commercial Coverage & Cash-flow VariabilityConsolidating territories and reduced account coverage can weaken local procedure growth and sales momentum. Combined with historically variable free cash flow and margin swings, this creates execution risk: slower commercial reach may delay recovery once reimbursement frictions ease, pressuring medium-term revenue.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is $1.48B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Aug 03, 2026 which is in 23 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on May 04, 2026. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.375.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Overvalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is -0.23.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,813,152 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -12.017%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.91 (-9.86% Downside)
$51.91 (-9.86% Downside)
Blogger Sentiment
Bullish
INSP Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.68%
12-Months-Change
Fundamentals
Return on Equity
17.98%
Trailing 12-Months
Asset Growth
24.71%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral — The company delivered modest revenue growth, margin expansion, stronger operating cash flow, a solid cash position, and meaningful clinical progress, but faces material near-term headwinds from coding and reimbursement uncertainty and the WISER pilot that prompted a significant revenue guide reduction and short-term profitability pressure. Management outlined actions to mitigate the disruption (education, field reimbursement hiring, inventory strategy, targeted investments) and expects improvement later in 2026, while a permanent coding solution (new CPT) is not expected until 2028.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$51.91
▼(-9.86% Downside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
TransMedics Group
―
PROCEPT BioRobotics
―
Ownership Overview
1.69% Insiders
28.73% Mutual Funds
3.07% Other Institutional Investors
39.64% Public Companies and
Individual Investors